Neuromuscular blocking medications are often used after the administration of anesthesia to relax the muscles and insert a breathing tube. While these medications aid anesthesiologists, they can leave lingering effects, including residual paralysis.
The new ASA guidelines are meant to reduce the likelihood of residual paralysis and quickly reverse muscle relaxation.
Eight new ASA recommendations and guidelines on neuromuscular blocking medication:
1. When medication is administered, do not just perform a clinical assessment alone.
2. Quantitative monitoring is recommended over qualitative assessment.
3. With quantitative monitoring, confirm a train-of-four ratio greater than or equal to 0.9.
4. Use the adductor pollicis muscle for monitoring.
5. Use eye muscles for neuromuscular monitoring.
6. Use sugammadex over neostigmine to avoid residual neuromuscular blockade.
7. Neostigmine can be used at a minimal depth.
8. Without quantitative monitoring, 10 minutes elapse from antagonism to extubation.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
